Abstract
Thromboembolic complications in individuals with high cardiometabolic risk are among the leading causes of cardiovascular mortality in the world. Rivaroxaban is an oral inhibitor of factor X (Stuart-Prower factor) approved for prevention of thromboembolic complications in many countries. The article evaluates clinical efficiency of rivaroxaban in reducing the possibility of development of thromboembolic complications in patients with high cardiometabolic risk with non-valvular atrial fibrillation coupled with obesity, arterial hypertension and hyperlipidemia.

This publication has 12 references indexed in Scilit: